Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brepocitinib in Active Psoriatic Arthritis
NCT03963401Phase 2Completed
- Sponsor
- Pfizer
- Start
- Jun 2019
- Primary completion
- Apr 2020
- Modality
- Small Molecules
- Countries
- 11
01
Overview
A Phase 2 trial of brepocitinib in psoriatic arthritis (PsA), sponsored by Pfizer. Started Jun 2019; status: completed.
02
Drugs
brepocitinib
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on NCT03963401.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03963401.